A trial tested an enhanced recovery after surgery (ERAS) protocol in patients who underwent ambulatory transurethral resection (TURBT) of bladder cancer.
MedPage Today on MSN
Organ-Sparing Strategy 'Promising' in Muscle-Invasive Bladder Cancer
Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...
Cancer patients on the Isle of Wight are benefiting from faster treatment and shorter hospital stays. Improvements at St Mary ...
The benefit-risk profile was favorable, supporting UGN-102 mitomycin gel as a nonsurgical alternative to TURBT in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder ...
UGN-102 showed high complete response rates in both ENVISION and ATLAS trials for low-grade, intermediate-risk NMIBC. Dysuria was the most common side effect of UGN-102, with other side effects ...
Morning Overview on MSN
Bladder cancer warning signs you can’t ignore and how doctors treat it
Bladder cancer frequently announces itself through symptoms that patients dismiss as minor urinary issues, and that delay between first sign and diagnosis can mean the difference between a ...
Bipolar transurethral resection represents a significant evolution in the surgical management of bladder cancer, particularly for non‐muscle invasive bladder cancer (NMIBC). This technique utilises an ...
Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results